| CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients CJ Turtle, LA Hanafi, C Berger, TA Gooley, S Cherian, M Hudecek, ... The Journal of clinical investigation 126 (6), 2123-2138, 2016 | 2136 | 2016 |
| Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells J Gust, KA Hay, LA Hanafi, D Li, D Myerson, LF Gonzalez-Cuyar, C Yeung, ... Cancer discovery 7 (12), 1404-1419, 2017 | 1200 | 2017 |
| Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells CJ Turtle, LA Hanafi, C Berger, M Hudecek, B Pender, E Robinson, ... Science translational medicine 8 (355), 355ra116-355ra116, 2016 | 1051 | 2016 |
| Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy KA Hay, LA Hanafi, D Li, J Gust, WC Liles, MM Wurfel, JA López, J Chen, ... Blood, The Journal of the American Society of Hematology 130 (21), 2295-2306, 2017 | 978 | 2017 |
| Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy R Gardner, D Wu, S Cherian, M Fang, LA Hanafi, O Finney, H Smithers, ... Blood, The Journal of the American Society of Hematology 127 (20), 2406-2410, 2016 | 758 | 2016 |
| Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, ... Journal of Clinical Oncology 35 (26), 3010-3020, 2017 | 694 | 2017 |
| HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells GG Gornalusse, RK Hirata, SE Funk, L Riolobos, VS Lopes, G Manske, ... Nature biotechnology 35 (8), 765-772, 2017 | 528 | 2017 |
| Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives J Godin-Ethier, LA Hanafi, CA Piccirillo, R Lapointe Clinical cancer research 17 (22), 6985-6991, 2011 | 436 | 2011 |
| Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy A Sheih, V Voillet, LA Hanafi, HA DeBerg, M Yajima, R Hawkins, V Gersuk, ... Nature communications 11 (1), 219, 2020 | 198 | 2020 |
| A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells N Pallet, I Sirois, C Bell, LA Hanafi, K Hamelin, M Dieudé, C Rondeau, ... Proteomics 13 (7), 1108-1120, 2013 | 106 | 2013 |
| Anti-CD19 chimeric antigen receptor-modified T Cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion … CJ Turtle, C Berger, D Sommermeyer, LA Hanafi, B Pender, EM Robinson, ... Blood 126 (23), 184, 2015 | 84 | 2015 |
| Graft-derived reconstitution of mucosal-associated invariant T cells after allogeneic hematopoietic cell transplantation A Bhattacharyya, LA Hanafi, A Sheih, JL Golob, S Srinivasan, MJ Boeckh, ... Biology of Blood and Marrow Transplantation 24 (2), 242-251, 2018 | 79 | 2018 |
| Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance J Godin-Ethier, S Pelletier, LA Hanafi, PO Gannon, MA Forget, JP Routy, ... The Journal of Immunology 183 (12), 7752-7760, 2009 | 62 | 2009 |
| Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B … CJ Turtle, LA Hanafi, C Berger, D Sommermeyer, B Pender, EM Robinson, ... Blood 126 (23), 3773, 2015 | 58 | 2015 |
| IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive J Godin-Ethier, LA Hanafi, JB Duvignaud, D Leclerc, R Lapointe Molecular immunology 49 (1-2), 253-259, 2011 | 39 | 2011 |
| Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes LA Hanafi, M Bolduc, MÈL Gagné, F Dufour, Y Langelier, MR Boulassel, ... Vaccine 28 (34), 5617-5626, 2010 | 32 | 2010 |
| Fludarabine downregulates indoleamine 2, 3-dioxygenase in tumors via a proteasome-mediated degradation mechanism LA Hanafi, D Gauchat, J Godin-Ethier, D Possamai, JB Duvignaud, ... PLoS One 9 (6), e99211, 2014 | 31 | 2014 |
| Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. CJ Turtle, LA Hanafi, C Berger, T Gooley, C Chaney, S Cherian, L Soma, ... Journal of Clinical Oncology 34 (15_suppl), 102-102, 2016 | 27 | 2016 |
| Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses G Sarikonda, M Mathieu, M Natalia, A Pahuja, Q Xue, PL Pierog, ... Cytometry Part B: Clinical Cytometry 100 (1), 79-91, 2021 | 24 | 2021 |
| Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. CJ Turtle, C Berger, D Sommermeyer, T Budiarto, LA Hanafi, K Melville, ... Journal of Clinical Oncology 33 (15_suppl), 3006-3006, 2015 | 23 | 2015 |
